Title:
ANTI-IL-17/VEGF BIFUNCTIONAL FUSION PROTEIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/083243
Kind Code:
A1
Abstract:
The present invention relates to the technical field of fusion proteins, and relates in particular to an anti-IL-17/VEGF bifunctional fusion protein and a use thereof. The anti-IL-17/VEGF bifunctional fusion protein comprises an anti-IL-17 antibody and a protein that specifically binds to VEGF .The protein that specifically binds to VEGF is VEGFR, and the protein that specifically binds to VEGF is connected to the anti-IL-17 antibody directly or by means of a linker. The anti-IL-17/VEGF bifunctional fusion protein may simultaneously block IL-17 and VEGF signaling pathways, and the anti-IL-17/VEGF bifunctional fusion protein may be used to prepare drugs for treating IL-17 and/or VEGF overexpression.
Inventors:
DENG LAN (CN)
HUANG HAOMIN (CN)
ZHU ZHENPIN (CN)
LIU LIFEN (CN)
WANG LIHUA (CN)
MENG YUN (CN)
HUANG HAOMIN (CN)
ZHU ZHENPIN (CN)
LIU LIFEN (CN)
WANG LIHUA (CN)
MENG YUN (CN)
Application Number:
PCT/CN2022/131063
Publication Date:
May 19, 2023
Filing Date:
November 10, 2022
Export Citation:
Assignee:
SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD (CN)
International Classes:
C07K19/00; A61K38/17; A61P17/00; A61P27/02; C12N5/10; C12N15/62; C12N15/63
Foreign References:
| CN111372950A | 2020-07-03 | |||
| CN109311974A | 2019-02-05 | |||
| CN112552410A | 2021-03-26 | |||
| CN107428824A | 2017-12-01 | |||
| US20200115443A1 | 2020-04-16 |
Attorney, Agent or Firm:
J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE (GENERAL PARTNERSHIP) (CN)
Download PDF: